

Bullous Dermatitis Antibodies

Accreditation Status:	UKAS Schedule of Accreditation								
Date Scheme started:	1995								
Clinical Applicability:	Diagnosis of Bullous Dermatitis (SER/009)								
Analytes:	Dermatitis Basement Membrane and Desmosome antibodies, anti-DSG-1 antibodies, anti-DSG-3 antibodies, anti-BP-180 antibodies and anti-BP-230 antibodies								
Units for Reporting:	Positive or Negative, U/mL, Ratio, or Titre as appropriate								
Samples Distributed:	Liquid format. Normal and pathological human serum								
Number of Distributions per year:	6								
Number of Samples per Distribution:	1								
Frequency of Distributions:	Every two months as outlined in the Distribution Schedule								
Schedule of Analysis:	Data entry is via the web for the submission of results. Data analysis is commenced 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics								
Data Analysis:	Qualitative responses are assessed by MI scoring in relation to the designated response								
Performance Scoring:	MI scoring and OMIS for all analytes for which the laboratory is registered								
Criteria of Performance:	Laboratory performance is assessed over a running analytical window of 6 Distributions (12 months) The categories of performance are: <table><thead><tr><th></th><th><u>Total MIS</u></th></tr></thead><tbody><tr><td>Good</td><td>Zero</td></tr><tr><td>Adequate</td><td>1</td></tr><tr><td>Poor</td><td>>1</td></tr></tbody></table>		<u>Total MIS</u>	Good	Zero	Adequate	1	Poor	>1
	<u>Total MIS</u>								
Good	Zero								
Adequate	1								
Poor	>1								
Persistent Poor Performance:	Defined as being in the Poor Performance category for two or more successive Distributions								